Date published: 2025-9-10

1-800-457-3801

SCBT Portrait Logo
Seach Input

OR52N4 Inhibitors

OR52N4 inhibitors are a specific class of chemical compounds that target the OR52N4 receptor, a member of the olfactory receptor family, which belongs to the larger G-protein-coupled receptor (GPCR) superfamily. Olfactory receptors like OR52N4 are primarily recognized for their role in detecting odorants in the nasal epithelium, but they are also expressed in a variety of other tissues, suggesting potential roles beyond olfaction. The function of OR52N4 in these non-olfactory tissues remains an area of active research. Inhibitors of OR52N4 are designed to interfere with the normal activity of this receptor, potentially modulating the physiological processes in which OR52N4 is involved. These inhibitors work by binding to the receptor in a manner that blocks or diminishes its ability to interact with its natural ligands, thereby altering the receptor's signaling pathways. The chemical nature of OR52N4 inhibitors can vary widely, encompassing different structural classes and mechanisms of action. These compounds might bind directly to the receptor's ligand-binding domain, effectively competing with endogenous ligands, or they could bind allosterically, inducing conformational changes that impair receptor function. The development of these inhibitors typically involves detailed structural analysis of OR52N4, often using techniques such as X-ray crystallography, nuclear magnetic resonance (NMR), and computational modeling to identify key binding sites and design molecules that can selectively target the receptor. The study of OR52N4 inhibitors is crucial for understanding the broader biological roles of this receptor and how its inhibition can influence various cellular processes. Researchers focus on optimizing the potency, specificity, and selectivity of these inhibitors to ensure they effectively modulate OR52N4 activity without affecting other receptors or proteins, which is essential for elucidating the precise functions of OR52N4 in different biological systems.

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

5-Azacytidine

320-67-2sc-221003
500 mg
$280.00
4
(1)

This cytidine analog may interfere with the methylation pattern of the OR52N4 gene's promoter region, potentially leading to its transcriptional silencing if methylation is ordinarily required for its expression.

Trichostatin A

58880-19-6sc-3511
sc-3511A
sc-3511B
sc-3511C
sc-3511D
1 mg
5 mg
10 mg
25 mg
50 mg
$149.00
$470.00
$620.00
$1199.00
$2090.00
33
(3)

As an inhibitor of histone deacetylases, Trichostatin A could result in the hyperacetylation of histones near the OR52N4 gene, possibly leading to the compacting of chromatin and subsequent transcriptional repression of this gene.

Valproic Acid

99-66-1sc-213144
10 g
$85.00
9
(1)

This compound could cause hyperacetylation of histones associated with the OR52N4 gene, which may result in chromatin condensation and a subsequent decrease in OR52N4 expression levels.

Retinoic Acid, all trans

302-79-4sc-200898
sc-200898A
sc-200898B
sc-200898C
500 mg
5 g
10 g
100 g
$65.00
$319.00
$575.00
$998.00
28
(1)

Retinoic Acid could activate transcription factors that repress the OR52N4 gene, leading to reduced transcriptional activity and lower protein levels.

Actinomycin D

50-76-0sc-200906
sc-200906A
sc-200906B
sc-200906C
sc-200906D
5 mg
25 mg
100 mg
1 g
10 g
$73.00
$238.00
$717.00
$2522.00
$21420.00
53
(3)

This antibiotic binds to the DNA helix, obstructing RNA polymerase action on the OR52N4 gene, which would result in decreased mRNA synthesis and protein production.

Methotrexate

59-05-2sc-3507
sc-3507A
100 mg
500 mg
$92.00
$209.00
33
(5)

By inhibiting dihydrofolate reductase, Methotrexate could disrupt one-carbon metabolism, leading to altered methylation patterns and potential downregulation of OR52N4 expression.

Mithramycin A

18378-89-7sc-200909
1 mg
$54.00
6
(1)

If the OR52N4 gene promoter encompasses Sp1-binding sites, Mithramycin A could bind these sequences, blocking Sp1 transcription factor access and leading to decreased OR52N4 transcription.

Chloroquine

54-05-7sc-507304
250 mg
$68.00
2
(0)

Chloroquine could inhibit lysosomal enzymes and alter the endosomal system, which may disrupt mRNA trafficking or degradation pathways, potentially leading to reduced levels of OR52N4 mRNA.

(−)-Epigallocatechin Gallate

989-51-5sc-200802
sc-200802A
sc-200802B
sc-200802C
sc-200802D
sc-200802E
10 mg
50 mg
100 mg
500 mg
1 g
10 g
$42.00
$72.00
$124.00
$238.00
$520.00
$1234.00
11
(1)

EGCG could bind directly to the DNA of the OR52N4 gene or interact with transcription factors specific to the OR52N4 promoter, leading to a targeted reduction in gene expression.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

By inhibiting the PI3K pathway, which may be involved in the transcriptional activation of OR52N4, LY294002 could lead to a decrease in the expression of the OR52N4 gene.